| Literature DB >> 30875364 |
Herbert Sizek1, Andrew Hamel1, Dávid Deritei2,3, Sarah Campbell1, Erzsébet Ravasz Regan1.
Abstract
The PI3K/AKT signaling pathway plays a role in most cellular functions linked to cancer progression, including cell growth, proliferation, cell survival, tissue invasion and angiogenesis. It is generally recognized that hyperactive PI3K/AKT1 are oncogenic due to their boost to cell survival, cell cycle entry and growth-promoting metabolism. That said, the dynamics of PI3K and AKT1 during cell cycle progression are highly nonlinear. In addition to negative feedback that curtails their activity, protein expression of PI3K subunits has been shown to oscillate in dividing cells. The low-PI3K/low-AKT1 phase of these oscillations is required for cytokinesis, indicating that oncogenic PI3K may directly contribute to genome duplication. To explore this, we construct a Boolean model of growth factor signaling that can reproduce PI3K oscillations and link them to cell cycle progression and apoptosis. The resulting modular model reproduces hyperactive PI3K-driven cytokinesis failure and genome duplication and predicts the molecular drivers responsible for these failures by linking hyperactive PI3K to mis-regulation of Polo-like kinase 1 (Plk1) expression late in G2. To do this, our model captures the role of Plk1 in cell cycle progression and accurately reproduces multiple effects of its loss: G2 arrest, mitotic catastrophe, chromosome mis-segregation / aneuploidy due to premature anaphase, and cytokinesis failure leading to genome duplication, depending on the timing of Plk1 inhibition along the cell cycle. Finally, we offer testable predictions on the molecular drivers of PI3K oscillations, the timing of these oscillations with respect to division, and the role of altered Plk1 and FoxO activity in genome-level defects caused by hyperactive PI3K. Our model is an important starting point for the predictive modeling of cell fate decisions that include AKT1-driven senescence, as well as the non-intuitive effects of drugs that interfere with mitosis.Entities:
Mesh:
Substances:
Year: 2019 PMID: 30875364 PMCID: PMC6436762 DOI: 10.1371/journal.pcbi.1006402
Source DB: PubMed Journal: PLoS Comput Biol ISSN: 1553-734X Impact factor: 4.475
Fig 3Modular Boolean model reproduces the expected quiescent, apoptotic, and cell cycle phenotypes in various extracellular environments.
(A) Stable attractor states of isolated regulatory switches. Blue / light brown / purple / dark red boxes: stable states of the Restriction / Origin of Replication Licensing / Phase / Apoptotic Switch. Orange / blue node border: ON / OFF state. (B) Network representation of the Boolean model partitioned into regulatory switches and processes. Gray: inputs representing environmental factors; green: Growth Signaling; dark red: Apoptotic Switch; light brown: Origin of Replication Licensing Switch; blue: Restriction Switch; purple: Phase Switch; orange: cell cycle processes and molecules that bridge between the multi-stable modules. Black →: activation; red ⊣: inhibition. (C) Cell phenotypes predicted for every combination of no/low/high growth-factor (x axis) and Trail exposure (y axis). The network-wide ON/OFF states of each attractor and the molecular signatures that define their phenotypes are detailed in . Blue fragmented cell: apoptotic states (#1–6); gray elongated cell: quiescent/non-dividing states (#7–8); cell with mitotic spindle: cell undergoing repeated cycles (#9). Yellow circle around nucleus: 4N DNA content; double-/single-headed arrows between cells: reversible/ irreversible phenotypic transitions in response to changing environments; green arrow: change in growth factor levels; red: change in Trail exposure. Image credits: apoptotic cell [78]; quiescent cell: ; mitotic spindle: .
Model attractors reproduce experimentally observed cell phenotypes.
| Model behavior | Experimentally observed cell behavior | Cell type | Reference | |
|---|---|---|---|---|
| • Deterministic stimulation with | Saturating concentration of | JURKAT (immortalized human T lymphocytes) | Fig 2 in [ | |
| 7 human pancreatic cancer cell lines | Fig 1 in [ | |||
| MCF10A (immortalized, non-transformed human mammary epithelial cells) | Fig 1D in [ | |||
| T98G (human glioblastoma cell line) | Fig 1 in [ | |||
| • Deterministic stimulation with | Murine hematopoietic stem cells fully deprived of extracellular IL3 (a survival signal they depend on), exhibit 70–90% death in 36 hours. | FL5.12 (murine Hematopoietic stem cell line) | Fig 1B-C in [ | |
| HC11 cells in serum-free medium undergo apoptosis (~45% of cells die within four days), while | HC11 cells (mammary epithelial cells) | Fig 1B in [ | ||
| Cortical mouse astrocytes lacking the | cortical mouse astrocytes and neurons | Fig 1D, 2G, 4 in [ | ||
| • Deterministic stimulation with | An increasing fraction of rat embryonic fibroblasts entered the cell cycle at increasing serum concentrations from 0.02% to 3%. | rat embryonic fibroblasts | Fig 2–4 in [ | |
| An increasing fraction of MCF10A cells enter the cell cycle at increasing | MCF10A (immortalized, non-transformed human mammary epithelial cells) | Fig 1–2 in [ | ||
| Mouse fetal fibroblasts display wide heterogeneity in the timing of the G1 → S regardless of the level or duration of | C3H10T1/2 mouse fetal fibroblasts | Fig 6 in [ | ||
| • Deterministic stimulation with | At 5% bovine growth serum stimulation, ~100% of rat embryonic fibroblasts enter the cell cycle. | rat embryonic fibroblasts | Fig 2–4 in [ | |
| At 20ng/mL EGF in 5% horse serum stimulation, ~100% of MCF10As enter the cell cycle. | MCF10A (immortalized, non-transformed human mammary epithelial cells) | Fig 1–2 in [ | ||
Model reproduces experimentally documented dynamical behaviors.
| Model behavior | Experimentally observed cell behavior | Cell type | Ref. | ||
|---|---|---|---|---|---|
| Synchronous update | Biased asynchronous update | ||||
| • Continuously cycling cells ( | • In spite of irregular G1 gaps between consecutive rounds of division in continuously cycling cells ( | The catalytic submit of | MCF10A (human mammary epithelial cells) | Figs 2–3 in [ | |
| BEAS-2B (human bronchial epithelium) | Fig 6 in [ | ||||
| • Cells entering the cell cycle from quiescence display two | • In spite of variable G1 length in cells entering the cell cycle from quiescence, | Western blot for | NIH3T3 (primary mouse embryonic fibroblast cells, spontaneously immortalized) | Fig 1D in [ | |
| • Cells cannot enter the cell cycle in the absence of high | • Increasing levels of | High | MCF10A (human mammary epithelial cells). | Fig 5 in [ | |
| • Cells entering the cell cycle from quiescence pass the restriction point in late G1, after which they commit to a full division cycle. This event is marked by full activation of | Quiescent cells entering the cell cycle pass a point of no return called the restriction point marked by the full (and bimodal) activation of | rat embryonic fibroblasts | Fig 2–4 in [ | ||
| • Under saturating mitogenic stimulation, cycling cells can commit to another division cycle before finishing their current one, and thus can execute a full cell cycle in the absence of mitogenic stimulation ( | • Under strong mitogenic stimulation the asynchronous simulation produces a wide variety of G1 intervals. In the shortest of these, the | Rapidly dividing mammalian cells can pre-commit to a division cycle before finishing their current one. In this case, they execute a full cell cycle after mitogen withdrawal, such that their last exposure to mitogens occurs sometime during the previous G2 phase. | MCF10A (human mammary epithelial cells) | Fig 3 in [ | |
| • Under non-saturating mitogenic stimulation, cycling cells stochastically toggle between pre-commitment and a G0-like pause of various lengths ( | • The state transition graph of cycling cells shows two distinct groups of G1 states; one along the continuous cell cycle (the path of pre-commitment), and one that clusters apart (the G0-like pause). Return from this G0-like cluster of states generally goes through the late-G1 state along the cycle ( | Not all cells in the population pre-commit to another cycle. | |||
Model reproduces the experimentally documented effects of Plk1 knockdown and p110/PI3K/AKT1 over-expression / hyperactivity.
| Model behavior | Experimental evidence | |||
|---|---|---|---|---|
| Synchronous update | Asynchronous update | |||
| Loss of | Strong | |||
| Very strong | ||||
| Loss | ||||
| Strong | ||||
| Aneuploidy and genome duplication have been documented in | ||||
| Moderate | ||||
| Due to its role in driving contractile ring assembly (by recruiting the RhoGEF | ||||
| Weak | ||||
| Forced expression of | Expression of the constitutively active | |||
| Strong forced expression of | ||||
| Strong forced expression of | Genome doubling has been documented in a transgenic mouse model harboring overactive | |||
| Both | ||||
| Knockdown of | Cells expressing transcriptionally inactive | |||